

Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

Allison Fitzgerald¹, Nirohshah Trialonis-Suthakharan², Rachael Pattinson³, Jennifer Austin¹, Christine Bundy⁴, Matthias Augustin²

¹International Alliance of Dermatology Patient Organizations, Ottawa, Canada, ²University Medical Center Hamburg-Eppendorf, Germany, ³School of Dentistry, Cardiff University, UK, ⁴School of Healthcare Sciences, Cardiff University, UK.

BACKGROUND

The Global Research on the Impact of Dermatological Diseases (GRIDD) project has developed the **Patient-Reported Impact of Dermatological Diseases (PRIDD)**, a new measure of the impact and burden of dermatological conditions on the patient's life..



Target population

- Adults (≥ 18 years) worldwide living with a dermatological condition

Target construct

- Impact of dermatological conditions on the patient's life

Application

- Research and clinical practice

PRIDD RESULTS III - PSYCHOMETRIC TESTING

Survey 1		Survey 2	
504 participants; 35 conditions; 38 countries	Rasch analysis, structural validity, internal consistency, construct validity, floor and ceiling effects	272 participants; 27 conditions; 26 countries	Test-retest reliability, measurement error, responsiveness, Minimally Important Change (MIC)

2-4 week interval

SYSTEMATIC REVIEW



COSMIN
Consensus-based Standards for Selection of health Measurement Instruments

None of the existing 36 dermatology PROMs met the scientific standards.

ActaDV

Patient-Reported Outcome Measures in Dermatology: A Systematic Review

Rachael L. PATTINSON¹, Nirohshah TRIALONIS-SUTHAKHARAN², Sunnia GUPTA³, Alasdair L. HENRY^{4*}, Jacqueline F. LAVALLEE⁵, Marina OTTEN⁶, Timothy PICKLES⁷, Nick COURTIER⁸, Jennifer AUSTIN¹, Christine JANUS⁹, Matthias AUGUSTIN² and Chris BUNDY¹⁰
¹College of Biomedical and Life Sciences, School of Healthcare Sciences, Cardiff University, Cardiff, UK, ²Institute for Health Services Research in Dermatology and Nursing (IHDN), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, ³Big Health Ltd, London, UK, ⁴San Francisco, USA, ⁵Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, ⁶Division of Nursing, Midwifery and Social Work, University of Manchester, Manchester, ⁷Centre for Trials Research, Cardiff University, Cardiff, UK and ⁸International Alliance of Dermatology Patient Organizations, Ottawa, Canada

W	???	+++	?		+++	+++	B
++	+++	+++	+++	?	+++	?	A
W	???	W	W		-	W	B
W	???	+++	W		+++	W	B
W	++	++			+	W	B

W = weak evidence; + = sufficient evidence; - = insufficient evidence; ? = indeterminate evidence

A = Recommended for use


B = Potential to be recommended for use, but they require further research

C = Should not be recommended for use

Real world evidence is needed to determine minimally important change and responsiveness.

PRIDD RESULTS I – QUALITATIVE PATIENT INTERVIEW STUDIES

263 unique shared impacts of dermatological conditions were found, falling into five broad groups: **physical, psychological, social, financial, and daily life and responsibilities impacts**. We started drafting PRIDD using these 263 impacts and the **conceptual framework** shown here.



PATIENT ENGAGEMENT IN MEASURE DEVELOPMENT

Item Gathering: 2019-2020

- Workshop: 37 patients in 16 countries and 14 diseases
- Patient interviews: 28 patients in 11 countries and 5 diseases
- Outcome: 263 items

Delphi Surveys: 2020-2021

- 1154 patients in 61 countries and 90 diseases
- Outcome: 27 items

Cognitive Interviews: 2021

- 12 patients in 4 countries and 6 diseases
- Outcome: 26 items

Psychometrics Surveys: 2021-2022

- Survey #1: 486 patients (Completed Dec. 2021)
- Survey #2: Test - 504 patients completed July 2022; re-test – 272+ patients (Completed Sept. 2022)
- Outcome: 16 items

PRIDD RESULTS II - GLOBAL DELPHI SURVEY AND COGNITIVE INTERVIEWS

Patients prioritised **27 impact items for inclusion in the first draft of PRIDD**. The list of the **top 10 impacts** can inform research questions and initiatives that are of most important to patients.

Rank	Item	Impact group
1	My skin is sensitive	Physical
2	The quality, look and feel of my nails, skin, hair bothers me	Physical
3	I experience physical discomfort, soreness or irritation	Physical
4	I feel dismissed or abandoned by the healthcare system	Psychological
5	I cope by living a healthy lifestyle	Psychological
6	My leisure time/activities are affected	Daily life and responsibilities
7	I have been affected financially	Financial
8	My life choices are affected (e.g. choice to have children)	Psychological
9	I rely on others to help me cope	Psychological
10	My daily routine has had to accommodate my condition	Daily life and responsibilities

The first draft was pilot-tested with 12 patients, representing 6 dermatological conditions and 4 countries. It produced a **26-item version of PRIDD with evidence of content validity, feasibility, and acceptability from patients**.

DISCUSSION

PRIDD is the **only validated dermatology impact measure applicable to all skin conditions**. It is the first PROM in dermatology to be developed and validated in partnership with patients.



96 COUNTRIES



OVER 5600 PATIENTS

OVER 7 YEARS

PRIDD MEASURE

PRIDD

This multidimensional measure is valid, reliable and ready for use with adult patients across all dermatological conditions. It assesses four areas of impact: physical, life responsibilities, psychological and social.

FEATURES

BY THE PATIENT TO TRACK THEIR DISEASE

VALID AND RELIABLE

EXTENSIVELY PUBLISHED

AVAILABLE IN 15+ LANGUAGES

CLINICAL TRIALS

ELECTRONIC & PAPER FORMATS

REFLECTS TRUE BURDEN OF ALL SKIN DISEASES

16 QUESTIONS IN LESS THAN 2 MINUTES

OTHER RESEARCH

Download the app

Implication for patient use: PRIDD highlights the **need for holistic support addressing psychological, physical, and lifestyle factors in dermatology care**. PRIDD can be used in partnership with patients to better understand patient suffering – by the patient to track their disease; in clinical practice; in clinical trials; and in other research.

Implications for research: GRIDD produced a **novel (and repeatable) methodology** for developing patient-relevant outcome measures (or PROMS) that be used across disease areas.

